Société de Therapeutique Marocaine S.A. (CBSE:SOT)
Morocco
· Delayed Price · Currency is MAD 1,599.00
0.00 (0.00%)
At close: Jun 6, 2025
CBSE:SOT Income Statement
Financials in millions MAD. Fiscal year is January - December.
Millions MAD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 2,816 | 2,486 | 2,302 | 2,056 | 1,798 | Upgrade
|
| Revenue | 2,816 | 2,486 | 2,302 | 2,056 | 1,798 | Upgrade
|
| Revenue Growth (YoY) | 13.27% | 8.00% | 11.96% | 14.35% | 6.66% | Upgrade
|
| Cost of Revenue | 1,488 | 1,335 | 1,203 | 1,035 | 914.07 | Upgrade
|
| Gross Profit | 1,328 | 1,151 | 1,099 | 1,021 | 883.78 | Upgrade
|
| Selling, General & Admin | 730.61 | 683.37 | 604.7 | 542.4 | 471.43 | Upgrade
|
| Other Operating Expenses | -0.59 | 17.99 | -45.83 | -35.86 | -27.72 | Upgrade
|
| Operating Expenses | 797.98 | 756 | 616.05 | 561.16 | 488.33 | Upgrade
|
| Operating Income | 529.81 | 394.96 | 482.66 | 459.41 | 395.45 | Upgrade
|
| Interest Expense | -31.21 | -20.36 | -10.03 | -9.11 | -11.08 | Upgrade
|
| Interest & Investment Income | 0.64 | 0.47 | 0.46 | 0.38 | 1.3 | Upgrade
|
| Earnings From Equity Investments | -0.64 | -0.33 | -0.02 | -0.12 | -0.13 | Upgrade
|
| Currency Exchange Gain (Loss) | 11.43 | 18.29 | 3.98 | 2.86 | -1.33 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.4 | 0.98 | 2.48 | -0.07 | -0.89 | Upgrade
|
| EBT Excluding Unusual Items | 510.42 | 394.01 | 479.54 | 453.35 | 383.33 | Upgrade
|
| Gain (Loss) on Sale of Investments | 13.17 | - | -6.54 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 73.34 | 0 | 0.03 | 1.52 | Upgrade
|
| Asset Writedown | -30.88 | -31.7 | -27.95 | -32.79 | -33.11 | Upgrade
|
| Other Unusual Items | - | -48.06 | -28.13 | -13.17 | -9.02 | Upgrade
|
| Pretax Income | 492.71 | 387.6 | 416.92 | 407.42 | 342.72 | Upgrade
|
| Income Tax Expense | 175.48 | 123.85 | 149.79 | 132.48 | 112.46 | Upgrade
|
| Earnings From Continuing Operations | 317.22 | 263.75 | 267.13 | 274.95 | 230.27 | Upgrade
|
| Minority Interest in Earnings | -1.94 | -0.99 | -0.52 | 3.9 | -0.07 | Upgrade
|
| Net Income | 315.29 | 262.76 | 266.62 | 278.85 | 230.2 | Upgrade
|
| Net Income to Common | 315.29 | 262.76 | 266.62 | 278.85 | 230.2 | Upgrade
|
| Net Income Growth | 19.99% | -1.45% | -4.39% | 21.13% | 4.82% | Upgrade
|
| Shares Outstanding (Basic) | 7 | 7 | 7 | 7 | 7 | Upgrade
|
| Shares Outstanding (Diluted) | 7 | 7 | 7 | 7 | 7 | Upgrade
|
| EPS (Basic) | 43.79 | 36.49 | 37.03 | 38.73 | 31.97 | Upgrade
|
| EPS (Diluted) | 43.79 | 36.49 | 37.00 | 38.70 | 31.97 | Upgrade
|
| EPS Growth | 19.99% | -1.37% | -4.39% | 21.04% | 4.83% | Upgrade
|
| Free Cash Flow | 120.94 | -17.72 | 86.33 | 265.13 | 34.68 | Upgrade
|
| Free Cash Flow Per Share | 16.80 | -2.46 | 11.99 | 36.82 | 4.82 | Upgrade
|
| Dividend Per Share | 28.000 | 17.000 | 25.000 | 25.000 | 5.250 | Upgrade
|
| Dividend Growth | 64.71% | -32.00% | - | 376.19% | - | Upgrade
|
| Gross Margin | 47.15% | 46.30% | 47.73% | 49.64% | 49.16% | Upgrade
|
| Operating Margin | 18.82% | 15.89% | 20.97% | 22.35% | 22.00% | Upgrade
|
| Profit Margin | 11.20% | 10.57% | 11.58% | 13.56% | 12.80% | Upgrade
|
| Free Cash Flow Margin | 4.29% | -0.71% | 3.75% | 12.90% | 1.93% | Upgrade
|
| EBITDA | 574.41 | 449.6 | 539.84 | 514.04 | 440.07 | Upgrade
|
| EBITDA Margin | 20.40% | 18.09% | 23.45% | 25.00% | 24.48% | Upgrade
|
| D&A For EBITDA | 44.61 | 54.64 | 57.18 | 54.63 | 44.62 | Upgrade
|
| EBIT | 529.81 | 394.96 | 482.66 | 459.41 | 395.45 | Upgrade
|
| EBIT Margin | 18.82% | 15.89% | 20.97% | 22.35% | 22.00% | Upgrade
|
| Effective Tax Rate | 35.62% | 31.95% | 35.93% | 32.52% | 32.81% | Upgrade
|
| Advertising Expenses | 53.82 | 55.26 | 52.09 | 45.89 | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.